Latest news with #TheJournaloftheAmericanMedicalAssociation
Time of India
24-06-2025
- Health
- Time of India
Study links early puberty with higher chance of mental health problems
New Delhi: An earlier-than-usual onset of puberty could be related with a higher chance of mental health issues, with incidence of depression and ADHD remaining high for at least eight years following onset, a study has found. ' Central precocious puberty ' is a condition in which physical changes associated with this stage of growth begin early -- before age eight for girls, nine for boys. Researchers, including those from University Hospital Essen, Germany, looked at over 6,500 individuals -- around 1,100 who had early puberty and the rest who did not -- using the country's health insurance data, following them for 13 years. Findings, published in The Journal of the American Medical Association (JAMA) Network Open, show that those who attained puberty early were about 50 per cent more likely to be diagnosed with a mental condition, including depression, anxiety and behavioural disorders. Further, a diagnosis of depression could be 70 per cent more likely among those with an early onset of puberty, while that of anxiety disorders about 45 per cent more likely, the researchers found. "CPP (central precocious puberty) was associated with an increased risk of psychiatric disorders, with evidence supporting long-term mental health outcomes," the authors wrote. The findings suggest that "caretakers of children with (early puberty) should be vigilant for the emergence of psychiatric symptoms to initiate psychiatric care at an early stage." The team said that previous studies analysing how early puberty affects mental health in the future have yielded inconclusive and conflicting results, with value of research being low due to small sample sizes and limitations in methodology. This large-scale population-based study also found "long-term negative mental health consequences in patients with (early puberty), with increased incidence rates for depression and ADHD persisting up to (eight) years after diagnosis (of early puberty)."
Hans India
24-06-2025
- Health
- Hans India
Study links early puberty with higher chance of mental health problems
New Delhi: An earlier-than-usual onset of puberty could be related with a higher chance of mental health issues, with incidence of depression and ADHD remaining high for at least eight years following onset, a study has found. 'Central precocious puberty' is a condition in which physical changes associated with this stage of growth begin early -- before age eight for girls, nine for boys. Researchers, including those from University Hospital Essen, Germany, looked at over 6,500 individuals -- around 1,100 who had early puberty and the rest who did not -- using the country's health insurance data, following them for 13 years. Findings, published in The Journal of the American Medical Association (JAMA) Network Open, show that those who attained puberty early were about 50 per cent more likely to be diagnosed with a mental condition, including depression, anxiety and behavioural disorders. Further, a diagnosis of depression could be 70 per cent more likely among those with an early onset of puberty, while that of anxiety disorders about 45 per cent more likely, the researchers found. 'CPP (central precocious puberty) was associated with an increased risk of psychiatric disorders, with evidence supporting long-term mental health outcomes,' the authors wrote. The findings suggest that 'caretakers of children with (early puberty) should be vigilant for the emergence of psychiatric symptoms to initiate psychiatric care at an early stage.' The team said that previous studies analysing how early puberty affects mental health in the future have yielded inconclusive and conflicting results, with value of research being low due to small sample sizes and limitations in methodology. This large-scale population-based study also found 'long-term negative mental health consequences in patients with (early puberty), with increased incidence rates for depression and ADHD persisting up to (eight) years after diagnosis (of early puberty).'
Time of India
28-05-2025
- Health
- Time of India
Parkinson's disease four times more likely among people with autism, study suggests
New Delhi: People with autism could be four times more likely to develop Parkinson's disease later in life, according to a study among Swedish population. Autism is a neuro-developmental disorder affecting thought processes and social behaviour. It is diagnosed in early childhood, while Parkinson's disease is ageing-related neuro-degeneration, in which one experiences tremors in limbs and affected movement. "This indicates that there can be shared biological drivers behind ASD ( autism spectrum disorder ) and Parkinson's disease," first author Weiyao Yin, a researcher at the department of medical epidemiology and biostatistics, Karolinska Institutet, Sweden, said. The study, published in The Journal of the American Medical Association (JAMA) Neurology, analysed data from more than 22 lakh people born in the country between 1974 and 1999, who were followed from the age of 20 up to the end of 2022. Findings "suggest a potential shared etiology between neuro-developmental disorders and PD (Parkinson's disease), warranting increased awareness of long-term neurological conditions in individuals with ASD," the authors wrote. Yin said, "One hypothesis is that the brain's dopamine system is affected in both cases, since the neurotransmitter (brain chemical) dopamine plays an important part in social behaviour and motion control." While there is considerable evidence that dopamine production is affected in Parkinson's disease, the role of dopamine in autism is not yet clear, even though studies have shown that the brain chemical is involved, the researchers said. The researchers also took into account the fact that people diagnosed with autism are commonly prescribed anti-depressants and anti-psychotic drugs, which can cause Parkinson's-like symptoms. The link between autism and Parkinson's disease became less pronounced, "but the risk was still double", the researchers said. "The healthcare services need to keep people with ASD -- a vulnerable group with high co-morbidity and a high use of psychotropics -- under long-term observation," last author Sven Sandin, a statistician and epidemiologist at the department of medical epidemiology and biostatistics, Karolinska Institutet, said. "At the same time, it's important to remember that a Parkinson's diagnosis before the age of 50 is very rare, including for people with autism," Sandin said. The researchers pointed out that they only analysed early-onset Parkinson's disease before the age of 50 and that the average age of participants by the end of the study was 34. The incidence of Parkinson's disease was therefore very low -- 24 cases among 51,954 people with autism (0.05 per cent), and 438 among 22,26,611 people without autism (0.02 per cent). Future studies will need to examine if the elevated risk persists into older age, the team said. Global estimate of autism prevalence is one per cent, while in India, the estimate is 1.5 per cent, according to a 2023 study published in the Indian Journal of Pediatrics.
The Market Online
13-05-2025
- Health
- The Market Online
Trump revives effort to lower drug costs with new Executive Order
U.S. President Donald Trump announced on Monday that he will sign an executive order aimed at reducing the costs of certain medications The proposal targets specific drugs covered by Medicare and administered in medical offices, such as cancer treatments and other injectables Trump wants to cut U.S. drug prices, so they match those abroad, accusing Europe of practices that force up prices Canada produces an estimated US$3 billion in pharmaceuticals for the American market annually U.S. President Donald Trump announced on Monday that he will sign an executive order aimed at reducing the costs of certain medications, reviving a failed initiative from his first term. The order directs the Department of Health and Human Services to tie Medicare payments for medications administered in a doctor's office to the lowest prices paid by other countries. The proposal targets specific drugs covered by Medicare and administered in medical offices, such as cancer treatments and other injectables. Medicare, which provides health insurance for roughly 70 million older Americans, has long faced criticism for high drug prices compared to other wealthy nations. Trump's 'most favoured nation' approach aims to align U.S. drug prices with those of economically advanced countries. This policy could impact drugs like bupropion, ibalizumab, and sotalol, which are primarily manufactured in Canada and exported to the U.S. A research letter published in The Journal of the American Medical Association highlighted the potential impact of tariffs on Canadian pharmaceuticals. The letter identified hundreds of drugs made in Canada for the U.S. market, with dozens being predominantly manufactured in Canada. Canada produces an estimated US$3 billion in pharmaceuticals for the American market annually. A proposed 25 per cent tariff on these drugs could add US$750 million in costs for buyers, potentially affecting pharmacies and consumers. Trump's executive order represents a significant step in addressing the long-standing issue of high drug prices in the U.S., but its success will depend on the cooperation of pharmaceutical companies and the implementation of the 'most favored nation' pricing model Join the discussion: Find out what everybody's saying about health care stocks on the health care Bullboards, and check out the rest of Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Time of India
07-05-2025
- Health
- Time of India
Chronic Pain Management: Study finds improving patient's ability to manage emotions could lower chronic pain, ET HealthWorld
Advt Advt Join the community of 2M+ industry professionals Subscribe to our newsletter to get latest insights & analysis. Download ETHealthworld App Get Realtime updates Save your favourite articles Scan to download App New Delhi: Improving one's ability to manage emotions has shown to be effective in dealing with chronic pain, according to a new pain, or the persistence of pain beyond the healing period of three months following physical injury, is estimated to affect about a third of the world's led by those from the University of New South Wales and Neuroscience Research Australia , trialled a behaviour therapy. It aimed at improving participants' ability to process emotions by de-escalating negative ones and enhancing positive the trial, eight online sessions of group therapy were conducted among 90 people experiencing chronic pain conditions, including lower back pain and fibromyalgia. The participants also used an app and handbook for of the trial, published in The Journal of the American Medical Association (JAMA) Network Open, show that over a period of six months, those receiving the behaviour therapy reported a better emotion regulation and reduced authors also found a "sustained improvement in depression symptoms and a clinically significant reduction in pain intensity"."By changing how we manage emotions, it is possible to change the experience of pain itself. This is not just a temporary relief but a potential long-term improvement in quality of life for those affected by chronic pain," author Sylvia Gustin, a psychologist and director of the NeuroRecovery Research Hub at the University of New South Wales, results could lead to new ways of treating chronic pain, emphasising the profound impact of emotional health on physical wellbeing, the authors said.A higher level of negative emotions, such as anger or worry, along with a lower capacity to manage them, have been shown to contribute towards the development of chronic pain.A study published in March in The Journal of the American Medical Association (JAMA) Network Open found that about 40 per cent of adults with chronic pain could be suffering from anxiety or depression."A key factor in disease progression is the inability to regulate negative emotions. This is disrupted by the impact of persistent pain on the brain's emotional circuitry. The resulting emotion dysregulation is an ill-understood and undertreated aspect of chronic pain, which we addressed in this trial," Gustin of low back pain -- a common chronic condition -- are projected at 843 million in 2050. It was estimated to affect 619 million in 2020, according to a study published in The Lancet Rheumatology journal in 2023.
